Eli Lilly and (LLY) Rating Reiterated by HC Wainwright

Eli Lilly and (NYSE:LLY)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued to investors on Wednesday.

Several other brokerages have also recently commented on LLY. Goldman Sachs cut shares of Eli Lilly and from a “buy” rating to a “neutral” rating and increased their target price for the stock from $86.98 to $95.00 in a report on Tuesday, January 16th. Jefferies Group set a $100.00 target price on shares of Eli Lilly and and gave the stock a “buy” rating in a report on Tuesday, January 16th. Argus upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and increased their target price for the stock from $85.52 to $115.00 in a report on Friday, January 5th. Credit Suisse Group cut shares of Eli Lilly and from a “neutral” rating to an “underperform” rating and set a $82.00 target price for the company. in a report on Monday, January 22nd. Finally, Bank of America reduced their target price on shares of Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating for the company in a report on Thursday, February 1st. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $93.16.

How to Become a New Pot Stock Millionaire

Eli Lilly and stock opened at $79.75 on Wednesday. The company has a market capitalization of $87,341.06, a PE ratio of 18.63, a P/E/G ratio of 1.46 and a beta of 0.26. Eli Lilly and has a twelve month low of $73.69 and a twelve month high of $89.09. The company has a quick ratio of 1.01, a current ratio of 1.32 and a debt-to-equity ratio of 0.85.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Wednesday, January 31st. The company reported $1.14 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.06. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. The business had revenue of $6.16 billion during the quarter, compared to analysts’ expectations of $5.93 billion. During the same quarter in the prior year, the company posted $0.95 earnings per share. The firm’s revenue was up 7.0% on a year-over-year basis. equities research analysts predict that Eli Lilly and will post 4.87 EPS for the current fiscal year.

In other news, SVP Jeffrey N. Simmons sold 9,625 shares of the stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $81.12, for a total value of $780,780.00. Following the transaction, the senior vice president now directly owns 152,120 shares of the company’s stock, valued at $12,339,974.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Donald A. Zakrowski sold 900 shares of the stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $81.09, for a total transaction of $72,981.00. Following the completion of the transaction, the insider now directly owns 4,130 shares in the company, valued at $334,901.70. The disclosure for this sale can be found here. In the last quarter, insiders sold 42,970 shares of company stock valued at $3,444,557. Corporate insiders own 0.11% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. Gradient Investments LLC bought a new position in shares of Eli Lilly and in the fourth quarter valued at about $103,000. Avestar Capital LLC bought a new position in shares of Eli Lilly and in the fourth quarter valued at about $100,000. Willingdon Wealth Management bought a new position in shares of Eli Lilly and in the third quarter valued at about $138,000. Front Row Advisors LLC bought a new position in shares of Eli Lilly and in the fourth quarter valued at about $137,000. Finally, Wealthcare Advisory Partners LLC bought a new position in shares of Eli Lilly and in the third quarter valued at about $142,000. 77.66% of the stock is currently owned by institutional investors.

WARNING: “Eli Lilly and (LLY) Rating Reiterated by HC Wainwright” was originally published by Week Herald and is the sole property of of Week Herald. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://weekherald.com/2018/04/20/eli-lilly-and-lly-rating-reiterated-by-hc-wainwright.html.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply